Time to Separate Persistent From Recurrent Differentiated Thyroid Cancer: Different Conditions With Different...

Area of Science:

• Oncology
• Endocrinology
• Cancer Research

Background:

• Differentiated thyroid cancer (DTC) generally has an excellent prognosis.
• However, up to 20% of DTC patients experience disease events post-initial treatment, categorized as persistent or recurrent disease.
• Distinguishing between persistent and recurrent disease is crucial for effective management.

Purpose of the Study:

• To compare the prevalence and outcomes of persistent versus recurrent differentiated thyroid cancer.
• To identify factors associated with persistent and recurrent disease in DTC patients.

Main Methods:

• Retrospective analysis of 4292 patients with DTC treated between 1990 and 2016.
• Mean follow-up of 6.5 years.
• Comparison of patient characteristics, disease patterns, and outcomes between persistent and recurrent disease groups.

Main Results:

• 14.9% of patients (639/4292) had disease events; 78% had persistent disease, and 22% had recurrent disease.
• Persistent disease was associated with older age, a lower female-to-male ratio, more structured disease, and significantly more distant metastases (38.4% vs 17.0%).
• Independent predictors for persistent disease included male sex, age, follicular histotype, T status (T3), and N status (N1b). Recurrent disease was associated with N status (N1b).

Conclusions:

• Persistent differentiated thyroid cancer (DTC) is more prevalent and associated with poorer outcomes compared to recurrent DTC.
• Early postoperative assessment of disease status is vital for optimizing treatment strategies and long-term follow-up in DTC management.
• Understanding the distinct characteristics of persistent and recurrent DTC can guide personalized patient care and improve prognostic accuracy.